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Relationship between serotonin transporter gene
polymorphisms and platelet serotonin transporter sites
among African-American cocaine-dependent individuals
and healthy volunteers
Alterations in the serotonin transporter (5-HTT) have been implicated in a variety of psychiatric
disorders including cocaine dependence. A polymorphism in the promoter region of the
serotonin transporter gene (5-HTTLPR) appears to influence the expression of 5-HTT in human
cell lines. We investigated whether 5-HTTLPR variants were related to differences in measures
of platelet 5-HTT sites in cocaine-dependent patients and healthy volunteers (controls).
Polymerase chain reaction-based genotyping of a 44 base pair insertion/deletion polymorphism
in 5-HTTLPR was performed in 138 cocaine-dependent African-American subjects and 60
African-American controls. This yielded a short (S) and a long (L) allele. Platelet 5-HTT sites
were measured using the tritiated paroxetine binding assay. Relationships of 5-HTTLPR
genotypes with Bmax (density of serotonin transporter) and Kd (affinity constant) were examined.
Bmax values were significantly lower in cocaine-dependent patients (640+/-233) than controls
(906+/-225) (P<0.001); however, 5-HTTLPR genotype distributions or allele frequencies did
not differ between the two groups. There were no significant differences in Bmax between the
three genotypes among cocaine-dependent patients (LL=690+/-246, LS=620+/-235, SS=587+/183; P=0.14) or controls (LL=909+/-233, LS=938+/-279, SS=866+/-143; P=0.65). All three
genotypes in cocaine-dependent patients showed comparable reductions in Bmax from the
corresponding genotypes in controls. Demographic variables, severity of substance use or
depression were unrelated to Bmax or 5-HTTLPR genotypes. Although platelet 5-HTT densities
are reduced in patients with cocaine dependence compared with healthy volunteers, these
genotypic variations in the serotonin transporter do not seem to influence levels of platelet 5HTT in cocaine-dependent patients or healthy volunteers.

Introduction
Considerable preclinical evidence indicates that serotonergic (5-HT) mechanisms may mediate
the central effects of cocaine (McMahon and Cunningham, 2001). Acutely, cocaine is found to
inhibit 5-HT uptake (Cunningham et al., 1996; Castanon et al., 2000), while repeated
administration of cocaine has been shown to reduce 5-HT levels in neurons (Heidbreder et al.,
1999). Alterations in 5-HT activity also modulate cocaine withdrawal (Baumann and Rothman,
1998) and influence cocaine-induced expression of early genes in the brain (Humblot et al.,
1998). Moreover, manipulations of the 5-HT system may influence rates of cocaine selfadministration among animals (Kleven and Koek, 1998). Relatively limited data are available
regarding 5-HT function in cocaine-dependent individuals, but the findings support animal
studies. For example, studies have reported impaired hormonal responses to 5-HT agents among
cocaine-dependent patients compared with controls (Buydens-Branchey et al., 1997;
Handelsman et al., 1998).
Among the various components of the 5-HT system, the serotonin transporter (5-HTT) is
critically important in regulating the reuptake of 5-HT into the presynaptic neuron and the

platelet, and serves as a target site for certain antidepressants (Graham and Langer, 1992;
Schloss and Williams, 1998). High affinity binding of the cocaine analogue [125I]RTI-55 to the
5-HTT sites in human brain has been demonstrated (Staley et al., 1994). Moreover, changes in
5-HTT have been reported in neuroimaging and post-mortem studies of cocaine-abusing
individuals (Little et al., 1998; Jacobsen et al., 2000). The human 5-HTT protein is found to be
encoded by a single gene, and a functional biallelic repeat polymorphism in the 5' promotor
region of 5-HTT (5-HTTLPR) yielding a short (S) and a long (L) variant of the allele has been
reported (Lesch et al., 1994; Gelernter et al., 1995). The S variant has been found to exert a
dominant effect and is associated with reduced transcriptional efficiency resulting in reduced 5HTT expression in lymphoblasts (Heils et al., 1996; Lesch et al., 1996). Studies of the 5HTTLPR polymorphism in substance abusers have yielded conflicting results. While 5HTTLPR variants have been associated with alcoholism in some studies (Sander et al., 1997;
Schuckit et al., 1999; Lichtermann et al., 2000), other studies of substance abusers have not
confirmed the association (Berrettini and Persico, 1996; Patkar et al., 2001; Kranzler et al.,
2002).
Investigations of the influences of 5-HTTLPR genotypes on the expression of the 5-HTT in
human platelets and neurons have not been consistent. While the short variant has been found to
be associated with reduced platelet binding (Bmax) (Stoltenberg et al., 2002) and reduced platelet
uptake (Vmax) (Hanna et al., 1998; Greenberg et al., 1999), other investigators have reported no
effect of the genotypes on both Vmax (Kaiser et al., 2002) and Bmax (Greenberg et al., 1999;
Preuss et al., 2000). Similarly, reports of a relationship between the 5-HTTLPR genotype and in
vivo 5-HTT availability that was observed in a neuroimaging study of healthy subjects (Heinz et
al., 2000) could not be replicated in a similarly designed study (Willeit et al., 2001).
Most studies investigating the relationship of 5-HTTLPR genotypes with the expression of 5HTT have primarily recruited individuals of European background and investigated alcohol
dependence. There are relatively limited published data among African-American healthy
volunteers as well as among cocaine abusers, a major public health problem that particularly
affects minority populations. In a previous smaller sample we had observed that AfricanAmerican cocaine-dependent persons had significantly reduced platelet 5-HTT densities
compared with controls (Patkar et al., 2003). Since the density of platelet 5-HTT sites may be
influenced by genetic variations in the 5-HTTLPR, we first compared platelet 5-HTT between
cocaine-dependent patients and controls, and then investigated whether the platelet 5-HTT
densities were different among the 5-HTTLPR genotypes in patients with cocaine dependence
and controls. Finally, we examined each genotype of cocaine and control group with respect to
platelet 5-HTT measures to determine whether cocaine-associated alterations in 5-HTT occur
across all 5-HTTLPR genotypes.

Subjects
The data was collected from September 1997 to February 2002. One hundred and thirty-eight
subjects were recruited from individuals attending a university-affiliated, outpatient substance
abuse treatment program in Philadelphia. The study was annually approved by the Institutional
Review Board of Thomas Jefferson University, Philadelphia. Following a description of the
study, informed consent was obtained. The Structured Clinical Interview for DSM-IV Axis I
Disorders (First et al., 1997) was then administered. Subjects also underwent a medical history

review and physical examination. Exclusion criteria included a diagnosis of schizophrenia,
major depression, bipolar disorder, or schizoaffective disorder, having a serious medical illness,
pregnancy, and receiving psychotropic medications. If subjects used more than one substance,
they were included if their primary drug was cocaine. Urine drug screens were obtained for all
subjects.
Nearly 90% of the patients in the program were African-American. The sample was restricted to
African-American subjects to represent the clinical population and to reduce possible ethnic
variations in allele frequencies. Only subjects who had a history of substance abuse in one or
more immediate family members, who reported cocaine use in the previous 30 days on the
Addiction Severity Index (ASI), and who had onset of regular cocaine use before 25 years of
age were included. The family history was elicited by items on the family history section of the
ASI. The sample was restricted to individuals with early onset of regular cocaine use, inability
to sustain abstinence, and having one or more first-degree affected relatives to define a subset of
cocaine-dependent patients whose addiction may be more likely to influenced by genetic factors
(McGue et al., 1992).
Sixty consenting African-American controls were recruited from those responding to local
advertisements. Control subjects were screened using the Structured Clinical Interview for
DSM-IV Axis I disorders, urine drug screens, medical and family history review and physical
examination. They were excluded if they had a current or past history of substance abuse
(except tobacco), a major psychiatric disorder (schizophrenia, major depression or bipolar
disorder), serious medical disorders, a positive urine drug screen, were pregnant or were taking
psychotropic medications.

Assessments
Subjects and controls were assessed using the Beck Depression Inventory (BDI) (Beck and
Steer, 1987), and the ASI (McLellan et al., 1992). The ASI was performed only on cocainedependent subjects. The BDI is a widely-used, self-report questionnaire that assesses depressive
symptomatology during the previous week and requires about 10 min to complete. The ASI is a
40-min structured interview that has been extensively used for clinical and research purposes. It
assesses problem severity in seven domains of functioning: drug use, alcohol use,
employment/support, medical, legal, family/social and psychiatric. For each domain, a
composite score that ranges from 0 (minimum) to 1 (maximum) is provided to assess the
adequacy of functioning in these areas during the previous 30 days.

Genotyping
Genomic DNA was isolated from anticoagulated venous blood using standard techniques
(Miller et al., 1988). Genotyping for a 44 base pair insertion/deletion polymorphism in the 5'
promotor region was performed as described by Heils et al. (1996). Briefly, the 5-HTTLPR
region was amplified using polymerase chain reaction with oligonucleotide primers (5'GGCGTTGCCGCTCTGAATTGC and 5'-GAGGGACTGAGCTGGACAACCCAC) to
generate a 484 base pair (S) or a 528 base pair (L) fragment. The amplified fragments were
separated on agarose gels, and bands were visualized by ethidium bromide staining and

ultraviolet illumination. Genotypes were evaluated by investigators who were blind to the status
of the subject and any discrepancies were resolved by test replication.

[3H]Paroxetine binding assay
After a minimum of 2 weeks of abstinence from cocaine, 20 ml venous blood was collected in
ethylendiamine tetraacetic acid-containing tubes at room temperature and processed within 4 h
to harvest platelets. The platelet pellets were immediately frozen at -80[degrees]C until they
were assayed. Women were studied in the initial follicular phase of the menstrual cycle.
Paroxetine binding was performed using techniques described previously (Ozaki et al., 1994).
Protein concentrations were determined by the method of Lowry et al. (1951). Specific binding
of [3H]paroxetine binding (Life Science Products Inc, Boston, MA, USA) was determined at six
different concentrations in the presence and absence of fluoxetine (Sigma Labs, St Louis, MO,
USA). The intra-assay and interassay coefficients of variation for Bmax were 3.6% and 9.2%,
respectively. The scatchard analysis of the platelet [3H]paroxetine binding was performed using
the LIGAND software program to determine transporter densities (Bmax) and affinity constant
(Kd). The Bmax was expressed as fentomoles per milligram of protein while the Kd was
expressed as nanomoles per liter. The laboratory personnel were blind to the clinical data.

Statistical analyses
The allele frequencies and genotype distributions of the 5-HTTLPR variants were calculated for
cocaine-dependent patients and controls. Chi-square tests were used to compare allele
frequencies with those predicted by Hardy-Weinberg equilibrium based on allele frequencies
reported by Lesch et al. (1996). Bmax and Kd values were compared between cocaine-dependent
patients and controls, and between different genotypes of cocaine-dependent patients using t
tests (two-tailed) with corrections for unequal variances where necessary or one-way analysis of
variance (ANOVA) as appropriate. Correlations between variables were performed using
Pearson product moment or point biserial correlations as appropriate. All calculations were
performed using SPSS 11.0 software.

Power considerations
We tested the hypothesis that there was a functional difference in the 5-HTTLPR variants as
measured by [3H]paroxetine binding in cocaine-dependent subjects and controls. We initially
computed the power to detect significant differences in Bmax between subjects and controls
based on our previous studies of 5-HTT in cocaine-dependent patients and controls (Patkar et
al., 2003). With two-tailed alpha set at 0.05, the power to detect between-group differences in
Bmax in the current sample of 139 cocaine-dependent subjects and 60 controls was 0.99
(adjusted r2=0.19). The next set of analyses involved calculating the power to detect a
relationship between Bmax and 5-HTTLPR genotypes. Since we could not find published data in
cocaine-dependent patients, we relied on literature that found a significant relationship of 5HTTLPR genotypes with platelet 5-HTT binding in 54 alcoholic persons (Stoltenberg et al.,
2002). In this study the effect size (f) was strong (>0.4) as defined by Cohen (1988). We

assumed a more conservative effect size (f=0.30) for our study. With two-tailed alpha set at
0.05, and degrees of freedom at 2, the current study had a power of 0.86 and 0.99 to detect main
effects of the 5-HTTLPR genotype on 5HTT binding in 60 controls and 138 cocaine-dependent
patients, respectively. Based on these power considerations, we anticipated our sample size
would be sufficient to be able to address the research questions of the study.

Results
Sample

From a total of 212 African-American cocaine-dependent subjects and 108 controls who were
screened, 138 subjects and 60 controls fulfilled the inclusion criteria and had blood samples
analyzed for 5-HTT binding and 5-HTTLPR genotypes. The subjects (71% male) and controls
(61% male) did not differ significantly in gender ([chi]2=2.16, degrees of freedom=1, P=0.23).
However, subjects (36.11+/-6.12 were significantly older than controls (32.60+/-5.74) (t=3.88,
degrees of freedom=196, P<0.001). Also, subjects (84%) were significantly more likely to be
unemployed compared with controls (29%) ([chi]2=39.9, degrees of freedom=1, P<0.001).
Similarly, significant differences were observed between subjects (74% single) and controls
(46% single) in marital status ([chi]2=6.18, degrees of freedom=1, P<0.01). Cocaine-dependent
subjects scored significantly higher on the BDI (11.84+/-7.7) than controls (6.24+/-3.43)
(t=5.26, degrees of freedom=196, P<0.001). The mean age of first drug use was 20.3+/-4.2
years. Cocaine-dependent subjects had used cocaine for 15.5+/-7.7 years, the average use was
5.7+/-1.7 rocks per day. Over 80% used cocaine on a daily basis. The ASI composite scores in
various domains were as follows: medical (0.07+/-0.17), employment (0.87+/-0.28), drug
(0.24+/-0.21), alcohol (0.23+/-0.22), legal (0.04+/-0.15), family (0.13+/-0.20) and psychiatric
(0.17+/-0.21). The admission urine drug screens for 35% of the patients was positive for
cocaine, indicating that more than one-third patients were actively using cocaine at time of
admission. Of the 63% of patients who were abstinent, the average length of abstinence prior to
admission was 14.4 days. A significant proportion of the cocaine-dependent subjects had
additional current and lifetime substance abuse and dependence diagnoses. About 53% had
abused or were dependent on alcohol, approximately 82% were nicotine dependent, nearly 31%
were abusing or dependent on marijuana, and about 15% had opioid abuse or dependence
during their lifetime or at the present time.

Platelet [3H]paroxetine binding in cocaine-dependent patients and controls
Cocaine-dependent patients showed significantly lower Bmax (639.71+/-234.32) than controls
(905+/-225.34) (t=55.12, degrees of freedom=196, P<0.001). However, there was no significant
difference in Kd values between patients (0.24+/-0.21) and controls (0.26+/-0.17) (t=0.81,
degrees of freedom=196, P=0.42), and the correlation between Bmax and Kd values was not
statistically significant (r=0.11, P=0.19). The platelet counts did not differ significantly between
the patients with cocaine dependence (206+/-30 B/l) and control subjects (230+/-40 B/l). Since
the patients were significantly younger than the controls, we examined but found no significant
correlation between age and Bmax (r=0.11, P=0.18). Similarly, no correlation was observed

between paroxetine binding and demographic characteristics, including gender, employment
and marital status (all [chi]2<1.8, P>0.05 in each case). Also, there were no significant
correlations between paroxetine Bmax and BDI scores (r=-0.12, P=0.19). We then analyzed the
data to determine whether the pattern of cocaine use was related to paroxetine binding. No
significant correlations were observed between Bmax values on the one hand and quantity
(r=0.04), frequency (r=-0.09) or duration of cocaine use (r=-0.10), or age of first drug use
(r=0.07) on the other (P>0.05 in each case). We also examined and found no significant
difference in Bmax between patients who were actively using cocaine at the time of admission
(positive urine drug screens) and those who had negative admission urine drug screens
([chi]2=2.38). Also, no significant correlation was observed between length of abstinence and
Bmax (r=0.11, P=0.26).

Platelet [3H]paroxetine binding and 5-HTTLPR genotypes in cocaine-dependent patients
The genotype distributions of the 5-HTTLPR polymorphisms among cocaine-dependent
individuals are presented in Table 1. The allele frequencies were L=164 (59.4%) and S=112
(40.6%). The genotype distribution for cocaine-dependent subjects ([chi]2=0.98, degrees of
freedom=2, P=0.61) did not depart from that predicted from the Hardy-Weinberg equilibrium
(Lesch et al., 1996). ANOVA analyses revealed no significant differences in Bmax values
between the LL, LS and SS genotypes [F(2, 136)=2.03, P=0.14] (Table 1). Similarly, Kd values
were not significantly different among the three genotypes [F(2, 136)=0.81, P=0.44]. We also
analyzed the data by comparing the Bmax values in LL genotype (690+/-246) with those in a
combination of L/S and S/S genotype (611+/-224), assuming a dominant effect of the S allele,
and found no significant differences (t=1.71, degrees of freedom=136, P=0.11). Similarly, Kd
values did not differ between the LL and LS+SS genotype groups (t=0.46, degrees of
freedom=136, P=0.48). The distribution of Bmax among the three genotypes in cocainedependent patients is summarized in Figure 1.
No significant differences were observed in the distribution of sex among the different 5HTTLPR genotypes ([chi]2=1.36, degrees of freedom=2, P=0.43). The data was also analyzed
to determine whether the pattern of cocaine use was related to the transporter polymorphisms.
No significant associations were found between the 5-HTTLPR genotypes on the one hand and
admission urine drug screen ([chi]2=1.48, degrees of freedom=2, P=0.43), quantity (F=0.45,
P=0.62), frequency (F=0.41, P=0.66) or duration of cocaine use (F=0.37, P=0.70), age of first
drug use (F=0.82, P=0.44) or length of abstinence (F=1.19, P=0.21) on the other.
A significant proportion of the cocaine-dependent subjects had additional current and lifetime
substance abuse and dependence diagnoses, reflecting the clinical population in urban treatment
settings. However, no significant differences were found in 5-HTTLPR genotypes among
patients with cocaine dependence alone and those with current or lifetime alcohol dependence
and abuse (all [chi]2<2.02, P>0.05). With respect to other major substances (opioid and
marijuana) also, no relationship was observed between genotypes and Axis I substance use
diagnoses (all [chi]2<1.65, P>0.05).

Table 1

Figure 1

Platelet [3H]paroxetine binding and 5-HTTLPR genotypes in controls
Table 2 summarizes the genotype distributions of the 5-HTTLPR polymorphisms among
controls. The allele frequencies were L=68 (56.6%) and S=52 (43.4%). There was no departure
of the genotype distribution from that predicted from the Hardy-Weinberg equilibrium
([chi]2=0.43, degrees of freedom=2, P=0.87). Similar to findings among cocaine-dependent
patients, controls showed no significant differences in Bmax [F(2, 58)=0.43, P=0.65] or Kd [F(2,
58)=0.45, P=0.64] between the LL, LS and SS genotypes (Table 2). When the LL genotype was
compared with a combination of the L/S and S/S genotype, no significant differences were
found in Bmax (LL=934+/-242, LS+SS=922+/-218; t=0.85, degrees of freedom=58, P=0.39) or
Kd (t=0.62, degrees of freedom=58, P=0.47). The distribution of Bmax among the three
genotypes in cocaine-dependent patients is summarized in Figure 2. There was no significant
effect of gender ([chi]2=1.14, P>0.05) on genotype distribution in controls.
Table 2

Figure 2

Finally, we compared the Bmax values of each genotype in cocaine-dependent patients with the
corresponding genotype in controls (e.g. SS cocaine with SS controls). All three genotypes in
cocaine-dependent patients showed comparable but significant reductions in Bmax from the
corresponding genotypes in controls (t=4.21-5.28, degrees of freedom=31-96, P<0.01 in each
case).

Discussion
The study examined the association of 5-HTTLPR polymorphisms with platelet 5-HTT
measures in cocaine-dependent individuals and healthy volunteers. Contrary to our
expectations, 5-HTTLPR polymorphisms did not seem to influence 5-HTT parameters expected
to correlate with altered expression of the protein resulting from the polymorphism. The
genotype distribution and allele frequencies in our sample were not significantly different from
those reported among healthy volunteers (Lesch et al., 1996; Heinz et al., 2000) and alcoholic
subjects (Heinz et al., 2000; Stoltenberg et al., 2002).
Our results differ from findings from in vitro experiments (Lesch et al., 1996), platelet studies
(Stoltenberg et al., 2002), Single Photon Emission Computerized Tomography (SPECT)
investigations (Heinz et al., 2000) and postmortem studies (Little et al., 1998) indicating that 5HTTLPR genotypes may influence the 5-HTT expression in healthy volunteers and substance
abusers. In contrast to a 40-100% difference in mean densities of 5-HTT between LL
homozygotes and S-carriers that was observed in some of these studies (Lesch et al., 1996;
Stoltenberg et al., 2002), we found the corresponding values to differ by about 2% in controls
and about 11% in cocaine-dependent subjects. There could be several explanations for the
discrepant findings. Our power calculations were based on a relatively limited sample from the
literature (n=54) (Stoltenberg et al., 2002) and a type II error remains a possibility, because the
presumed effect size of the polymorphism may differ across various populations. Differences in
sample characteristics could be another explanation. Most of the studies have recruited
individuals of European background while our sample consisted entirely of African-American
individuals; the 5-HTTLPR alleles have been reported to be distributed differently across ethnic
groups (Lerman et al., 1998). Another reason could be differences in the 5-HTT binding
technique. For example, both Lesch's and Stoltenberg's groups used [125I]RTI-55 as a
radioligand, while we employed [3H]paroxetine for binding purposes. It is also possible that
modulation of the 5-HTT expression by the 5-HTTLPR polymorphism may not be detectable in
the presence of other influences on platelet 5-HTT regulation such as second messenger systems
and post-translational modifications (Greenberg et al., 1999; Zahniser and Doolen, 2001).
Finally, gene sequences other than those within the 5-HTTLPR may also regulate transcription
and affect 5-HT uptake (Flattem and Blakely, 2000; Kaiser et al., 2002).
It is worth noting that several well-designed studies involving reasonably sized samples have
failed to detect an association between platelet 5-HTT and 5-HTTLPR polymorphic variants
among healthy volunteers (Greenberg et al., 1999), individuals with obsessive compulsive
disorder (Hanna et al., 1998), unipolar and bipolar patients (Mellerup et al., 2001), and autistic
persons (Anderson et al., 2002). Our findings lend additional support to the negative literature.
The data are also consistent with a neuroimaging study of healthy volunteers that found no
association between 5-HTT availability and 5-HTTLPR polymorphisms (Willeit et al., 2001)
and similar results in postmortem brains of schizophrenic patients (Naylor et al., 1998). The

conflicting data in this area indicate that the pattern of 5-HTTLPR effects may vary in different
populations and environments (Stoltenberg and Burmeister, 2000).
All three genotypes in patients with cocaine dependence showed significant reductions in Bmax
from controls. Reduced platelet 5-HTT has been reported in several psychiatric disorders
including depression (Nemeroff et al., 1994) and alcoholism (Arranz et al., 1999). The question
whether the reduction in platelet 5-HTT densities among cocaine-dependent persons represent
trait or state phemonena remains unsettled. While we did not find an effect of 5-HTTLPR
genotypes on the platelet 5-HTT, we also failed to find an association between measures of
cocaine use and 5-HTT. Other studies have found an association of 5-HTTLPR with alcoholism
(Sander et al., 1997) and with response to alcohol (Schuckit et al., 1999). Given the limited data
in this area, more research is required to clarify whether 5-HTT alterations in substance abuse
may be related to genotypic variations.
Certain limitations of our study deserve comment. First, reflecting the clinical population,
cocaine-dependent individuals abused a variety of other substances; moreover, a high
proportion of patients and controls smoked tobacco. The additional substance use may have
affected platelet 5-HTT binding data. Second, there are potential problems of using volunteers
recruited from advertisements as controls, such as demographic differences and high rates of
personal and family histories of various illnesses (Adami et al., 2002). Third, although we
studied patients after 2 weeks of abstinence, this cannot exclude the effects of chronic cocaine
use on platelet 5-HTT sites. Fourth, while we excluded current Axis I disorders, Axis II
psychopathology was not assessed. Finally, it is possible that platelet 5-HTT may not mirror 5HTT sites in the brain even though the same gene encodes for the 5-HTT on platelets and
neurons (Lesch et al., 1993).
In conclusion, the present study could not detect an association between 5-HTTLPR genotypes
and densities of platelet 5-HTT among African-American cocaine-dependent individuals and
healthy volunteers. While platelet 5-HTT densities were reduced in cocaine-dependent persons
from controls, the reduction was comparable across the three genotypes. Considering the
evidence implicating the 5-HT system in cocaine dependence, further studies, preferably using
well-defined populations, are required to clarify the genetic influences on 5-HTT expression.
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